(Q43687125)

25 November 2017

title

Evaluation of cost-effectiveness of live oral pentavalent reassortant rotavirus vaccine introduction in Ghana (English)

1 reference

25 November 2017

0 references

0 references

0 references

0 references

1 reference

Collette Abbott

1

1 reference

25 November 2017

Benjamin Tiede

series ordinal

2

1 reference

25 November 2017

George Armah

series ordinal

3

1 reference

25 November 2017

Adel Mahmoud

series ordinal

4

1 reference

25 November 2017

Abbott, C.

0 references

Tiede, B.

0 references

Armah, G.

0 references

Mahmoud, A.

0 references

language of work or name

English

0 references

publication date

7 February 2012

1 reference

25 November 2017

2012

0 references

published in

Vaccine

1 reference

25 November 2017

volume

30

1 reference

25 November 2017

issue

15

1 reference

25 November 2017

page(s)

2582-2587

1 reference

http://ugspace.ug.edu.gh/handle/123456789/26904

25 November 2017

exact match

0 references

cites work

Diseases of poverty with high mortality in infants and children: malaria, measles, lower respiratory infections, and diarrheal illnesses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.076

Global, regional, and national causes of child mortality in 2008: a systematic analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.076

Anticipating rotavirus vaccines: epidemiology and surveillance of rotavirus in South Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.076

Rotavirus-associated medical visits and hospitalizations in South America: a prospective study at three large sentinel hospitals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.076

Rotavirus and severe childhood diarrhea

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.076

Rotavirus vaccines: current prospects and future challenges

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.076

Acute, infectious diarrhea among children in developing countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.076

Global Illness and Deaths Caused by Rotavirus Disease in Children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.076

Safety and Efficacy of an Attenuated Vaccine against Severe Rotavirus Gastroenteritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.076

Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.076

The promise of new rotavirus vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.076

Lessons from the US rotavirus vaccination program

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.076

Defeating rotavirus? The global recommendation for rotavirus vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.076

Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.076

Effect of Human Rotavirus Vaccine on Severe Diarrhea in African Infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.076

Changing patterns of rotavirus genotypes in Ghana: Emergence of human rotavirus G9 as a major cause of diarrhea in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.076

Incidence and risk factors of paediatric rotavirus diarrhoea in northern Ghana

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.076

Acute childhood diarrhoea in northern Ghana: epidemiological, clinical and microbiological characteristics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.076

Something old or something new? Social health insurance in Ghana

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.076

Economic and health burden of rotavirus gastroenteritis for the 2003 birth cohort in eight Latin American and Caribbean countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.076

Economic costs of rotavirus gastroenteritis and cost-effectiveness of vaccination in developing countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.076

Demographic variability, vaccination, and the spatiotemporal dynamics of rotavirus epidemics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.076

Epidemiology of rotavirus-associated hospital admissions in the province of Ferrara, Italy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.076

WHO Guide for standardisation of economic evaluations of immunization programmes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.076

Hospital Health Care Cost of Diarrheal Disease in Northern Ghana

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.076

The cost-effectiveness of rotavirus vaccination in Malawi

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.076

How much could rotavirus vaccines reduce diarrhea-associated mortality in northern Ghana? A model to assess impact

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.076

Effectiveness of pentavalent rotavirus vaccine against severe disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.076

Need for differential discounting of costs and health effects in cost effectiveness analyses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.076

Discounting for health effects in cost-benefit and cost-effectiveness analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.076

Estimating the costs of achieving the WHO-UNICEF Global Immunization Vision and Strategy, 2006-2015.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.076

Comparative review of three cost-effectiveness models for rotavirus vaccines in national immunization programs; a generic approach applied to various regions in the world

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.076

Cost-effectiveness of Rotavirus vaccination in Vietnam

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.076

Health care costs of diarrheal disease and estimates of the cost-effectiveness of rotavirus vaccination in Vietnam

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.076

Comparative evaluation of the potential impact of rotavirus versus HPV vaccination in GAVI-eligible countries: a preliminary analysis focused on the relative disease burden

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.076

10.1016/J.VACCINE.2012.01.076

7 January 2021

Identifiers

DOI

1 reference

25 November 2017

1 reference